Stocktoria
Samsung Biologics Co.,Ltd. 207940.KS
KR · Korea Exchange · XKRX · stock · Healthcare · website
Samsung Biologics Co.,Ltd. financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $4.56T | $3.50T | $3.69T | $3.00T |
| Gross profit | $2.52T | $1.71T | $1.80T | $1.47T |
| R&D expense | $37.2B | $36.7B | $81.6B | $45.9B |
| SG&A expense | $169.6B | $193.1B | $303.5B | $209.5B |
| Operating income | $2.07T | $1.32T | $1.11T | $983.6B |
| Interest expense | $29.2B | $34.1B | $81.6B | $64.1B |
| Income tax | $504.3B | $344.6B | $262.3B | $211.0B |
| Net income | $1.78T | $1.08T | $857.7B | $798.1B |
| EPS (diluted) | $26628.00 | $15221.00 | $12051.00 | $11432.00 |
| Operating cash flow | $2.25T | $1.66T | $1.67T | $953.0B |
| Free cash flow | $772.7B | $281.7B | $560.9B | -$56.2B |
| Cash & equivalents | $148.9B | $391.2B | $367.9B | $890.8B |
| Inventory | $2.13T | $2.82T | $2.64T | $2.38T |
| Total assets | $11.06T | $17.34T | $16.05T | $16.58T |
| Total liabilities | $3.61T | $6.43T | $6.22T | $7.60T |
| Shareholders' equity | $7.45T | $10.90T | $9.83T | $8.98T |
Growth · year-over-year · Revenue CAGR 14.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +30.3% | -5.3% | +23.1% | — |
| Net income growth | +64.7% | +26.3% | +7.5% | — |
| EPS growth | +74.9% | +26.3% | +5.4% | — |
| Free cash flow growth | +174.3% | -49.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · KR · as of 2025-12-31. Figures in KRW; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.